Background: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. Objective: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD). Methods: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts. Results: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor. Conclusions: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin / D. Healy, A. Bahrick, M. Bak, A. Barbato, R.S. Calabrò, B.M. Chubak, F. Cosci, A.B. Csoka, B. D'Avanzo, S. Diviccaro, S. Giatti, I. Goldstein, H. Graf, W.J.G. Hellstrom, M.S. Irwig, E.A. Jannini, P.K.C. Janssen, M. Khera, M.T. Kumar, J. Le Noury, M. Lew-Starowicz, D.E.J. Linden, C. Lüning, D. Mangin, C. Melcangi, O.W.M.A.A.S. Rodríguez, J.N. Panicker, A. Patacchini, A.M. Pearlman, C.F. Pukall, S. Raj, Y. Reisman, R.S. Rubin, R. Schreiber, S. Shipko, B. Vašečková, A. Waraich. - In: INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE. - ISSN 0924-6479. - 33:1(2022), pp. 65-76. [10.3233/JRS-210023]

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

S. Diviccaro;S. Giatti;C. Melcangi;
2022

Abstract

Background: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. Objective: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD). Methods: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts. Results: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor. Conclusions: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.
Post-SSRI sexual dysfunction; antidepressants; finasteride; isotretinoin; selective serotonin reuptake inhibitors
Settore MED/13 - Endocrinologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
jrs_2022_33-1_jrs-33-1-jrs210023_jrs-33-jrs210023.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 82.41 kB
Formato Adobe PDF
82.41 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/901759
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact